Clear Search sequence regions


  • brain (3)
  • city (1)
  • female (1)
  • health status (6)
  • heart failure (3)
  • heart rate (1)
  • humans (1)
  • kansas (1)
  • nt probnp (12)
  • patients (3)
  • status (1)
  • stroke (1)
  • treatment responses (1)
  • walk (1)
  • Sizes of these terms reflect their relevance to your search.

    We aim to validate NT-proBNP nonresponse score (NNRS) previously derived from the PROTECT and BATTLESCARRED studies in comparison with standard health status measures in predicting natriuretic peptide responses in patients with heart failure with reduced ejection fraction. Data on the GUIDE-IT trial were used to derive the NNRS based on 4 predictors including baseline NT-proBNP, heart rate, NYHA functional class, and history of atrial fibrillation. The discriminative capacity of the NNRS and health status measures for having NT-proBNP >1,000 pg/mL at 12 months was assessed and compared with baseline or follow-up health status measures including Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), Duke Activity Status Index (DASI), and 6-minute walk distance. Multivariable logistic regression analysis was used to determine the predictive value of the score and health status measures greater than the median values for NT-proBNP response with adjustment for age, sex, body mass index, comorbidities, baseline creatinine and NT-proBNP levels. Among 877 patients, 252 (28.7%) patients had NT-proBNP >1,000 pg/mL at 12 months. The discriminative capacity of the NT-proBNP nonresponse score was 0.72 (95% CI, 0.67-0.77). After adjusting for covariates, only NNRS (P = .044) and KCCQ-OSS (P = .002) remained predictive for NT-proBNP nonresponse at 12 months. NT-proBNP nonresponse score and KCCQ-OSS was associated with persistently elevated NT-proBNP 12 months independently of baseline NT-proBNP levels. Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

    Citation

    Thanat Chaikijurajai, Horng H Chen, W H Wilson Tang. Baseline NT-proBNP nonresponse score and health status measures in assessing treatment responses in heart failure with reduced ejection fraction. American heart journal. 2025 May;283:17-25

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 39870126

    View Full Text